PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical OncologyFederica Miglietta, Stefania Gori, Laura Cortesi et al.|The Breast|2022Cited by 16
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectivesStefania Gori, Riccardo Gerosa, Michela Cinquini et al.|Tumori Journal|2025Cited by 1